Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTRUSION: Intratumoral PK/PD of tusamitamab ravtansine (SAR408701) in metastatic NSCLC
2022-003451-34Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Mar 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tusamitamab ravtansine in non-small cell lung cancer (NSCLC), sponsored by Erasmus MC. Primary endpoint: Intratumoral DM4 concentration and tumor size change. Started Mar 2023; status: active.
02
Drugs
tusamitamab ravtansine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-003451-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003451-34.